Bjoern Lengenfelder, MD

Original Contribution

Long-Term Reduction of Mortality in the 4-Year Follow up of Tirofiban Therapy in Elective Percutaneous Coronary Interventions (TOPSTAR) Trial

03/25/2011

Joerg Strotmann , MD;

Georg Ertl , MD;

Wolfram Voelker , MD;

Andreas W. Bonz , MD;

Bjoern Lengenfelder , MD;

Stefan Stoerk , MD, PhD;

Lena Boes , MD;

ABSTRACT: Background. TOPSTAR was a randomized, placebo-controlled trial studying the effects of adding the glycoprotein IIb/IIIa inhibitor tirofiban to conventional treatment with aspirin and clopidogrel in patients undergoing elective...

ABSTRACT: Background. TOPSTAR...

03/25/2011

Journal of Invasive Cardiology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

March 27 ⁠–⁠ March 30

See Full Calendar

Bjoern Lengenfelder, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products